[1]中国医师协会介入医师分会临床诊疗指南专委会.肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识[J].介入放射学杂志,2022,31(11):1039-1044.
　Expert consensus on the TACE failure/refractoriness and its subsequent therapies in treating patients with hepatocellular carcinoma Clinical Guidelines Committee of Chinese College of Interventionalists[J].journal interventional radiology,2022,31(11):1039-1044.
点击复制

肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年11
页码:
1039-1044
栏目:
指南与共识
出版日期:
2022-12-13

文章信息/Info

Title:
Expert consensus on the TACE failure/refractoriness and its subsequent therapies in treating patients with hepatocellular carcinoma Clinical Guidelines Committee of Chinese College of Interventionalists
作者:
中国医师协会介入医师分会临床诊疗指南专委会
关键词:
【关键词】 癌; 肝细胞;  栓塞; 治疗性;  经动脉化疗栓塞;  抵抗;  专家共识
文献标志码:
A
摘要:
【摘要】 经动脉化疗栓塞（transarterial chemoembolization，TACE）是目前治疗肝细胞癌（hepatocellular carcinoma，HCC）最常用方法之一。然而，重复进行无效的TACE治疗可能会加重肝功能损伤，影响患者预后。“TACE抵抗（TACE failure/refractoriness）”这一概念，即是在此背景下为避免进行重复无效的TACE治疗而提出的。但已有的多个“TACE抵抗”定义彼此间尚存在分歧，且均存在一定的局限性，对中国HCC人群是否适用也有待商榷。由中国医师协会介入医师分会（Chinese College of Interventionalists，CCI）成立的“TACE抵抗”协作组结合现有的循证医学证据及国内专家意见，于2021年提出了符合中国临床实践的“TACE抵抗”CCI定义及专家共识。“TACE抵抗”定义为：经过连续3次及以上规范化、精细化TACE治疗后，末次术后1～3个月内通过增强CT/MRI检查并基于mRECIST标准进行评估，若肝内靶病灶与首次TACE治疗前相比仍处于疾病进展状态，则为发生“TACE抵抗”，须及时终止再次TACE而转换为其他治疗。本共识的发布旨在使“TACE抵抗”概念更具科学性，从而更好地指导临床实践，进一步提高中国HCC患者TACE治疗受益率。

参考文献/References:

［1］ Sung H， Ferlay J， Siegel RL， et al. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021， 71： 209- 249.
［2］ 中华人民共和国国家卫生健康委员会医政医管局． 原发性肝癌诊疗指南（2022年版）［J］． 临床肝胆病杂志， 2022， 21：288- 303．
［3］ Villanueva A. Hepatocellular carcinoma［J］. N Engl J Med， 2019， 380：1450- 1462.
［4］ Llovet JM， Kelley RK， Villanueva A， et al. Hepatocellular carcinoma［J］. Nat Rev Dis Primers， 2021， 7：6.
［5］ Marrero JA， Kulik LM， Sirlin CB， et al. Diagnosis， staging， and management of hepatocellular carcinoma：2018 practice guidance by the American association for the study of liver diseases［J］. Hepatology， 2018， 68： 723- 750.
［6］ European Association for the Study of the Liver. EASL clinical practice guidelines： management of hepatocellular carcinoma［J］. J Hepatol， 2018， 69：182- 236.
［7］ Reig M， Forner A， Rimola J， et al. BCLC strategy for prognosis prediction and treatment recommendation： the 2022 update［J］. J Hepatol， 2022， 76： 681- 693.
［8］ Llovet JM， Real MI， Montana X， et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma： a randomised controlled trial［J］. Lancet， 2002， 359： 1734- 1739.
［9］ Lo CM， Ngan H， Tso WK， et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepato- cellular carcinoma［J］. Hepatology， 2002， 35： 1164- 1171.
［10］ Kudo M， Matsui O， Izumi N， et al. Transarterial chemoem- bolization failure/refractoriness： JSH- LCSGJ criteria 2014 update［J］. Oncology， 2014， 87（Suppl 1）： 22- 31.
［11］ Cheng AL， Amarapurkar D， Chao Y， et al. Re- evaluating transarterial chemoembolization for the treatment of hepatocel- lular carcinoma： consensus recommendations and review by an International Expert Panel［J］. Liver Int， 2014， 34： 174- 183.
［12］ Raoul JL， Gilabert M， Piana G. How to define transarterial chemoembolization failure or refractoriness： a European perspec-tive［J］. Liver Cancer， 2014， 3： 119- 124.
［13］ Kudo M， Kawamura Y， Hasegawa K， et al. Management of hepatocellular carcinoma in Japan： JSH consensus statements and recommendations 2021 update［J］. Liver Cancer， 2021， 10： 181- 223.
［14］ Arizumi T， Ueshima K， Minami T， et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization（TACE） refractory and Intermediate- stage hepatocellular carcinoma［J］. Liver Cancer， 2015， 4： 253- 262.
［15］ Kudo M， Ueshima K， Ikeda M， et al. Randomised， multicentre prospective trial of transarterial chemoembolisation（TACE） plus sorafenib as compared with TACE alone in patients with hepato-cellular carcinoma： TACTICS trial［J］. Gut， 2020， 69： 1492- 1501.
［16］ Chen S， Shi M， Shen L， et al. Microwave ablation versus sorafenib for intermediate- stage hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness： a propensity score matching analysis［J］. Int J Hyperthermia， 2020， 37： 384- 391.
［17］ Ogasawara S， Chiba T， Ooka Y， et al. Efficacy of sorafenib in intermediate- stage hepatocellular carcinoma patients refractory to transarterial chemoembolization［J］. Oncology， 2014， 87： 330- 341.
［18］ Arizumi T， Minami T， Chishina H， et al. Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1 and B2［J］. Dig Dis， 2017， 35：589- 597.
［19］ Kokudo N， Takemura N， Hasegawa K， et al. Clinical practice guidelines for hepatocellular carcinoma： the Japan Society of Hepatology 2017（4th JSH- HCC guidelines） 2019 update［J］. Hepatol Res， 2019， 49：1109- 1113.
［20］ Chen S， Peng Z， Zhang Y， et al. Lack of response to transarterial chemoembolization for intermediate- stage hepatocellular carci-noma： abandon or repeat?［J］. Radiology， 2021， 298： 680- 692.
［21］ 余晨曦，滕皋军． 经导管动脉化疗栓塞术抵抗研究进展［J］． 介入放射学杂志， 2017， 26：1063- 1067．
［22］ Zhang S， Zhong BY， Zhang L， et al. Transarterial chemoem-bolization failure/refractoriness： a scientific concept or pseudo- proposition［J］. World J Gastrointest Surg， 2022， 14： 528- 537.
［23］ Zhong BY， Wang WS， Zhang S， et al. Re- evaluating transarterial chemoembolization failure/refractoriness： a survey by Chinese College of Interventionalists［J］. J Clin Transl Hepatol， 2021， 9： 521- 527.
［24］ Park JW， Chen M， Colombo M， et al. Global patterns of hepatocellular carcinoma management from diagnosis to death： the BRIDGE Study［J］. Liver Int， 2015， 35： 2155- 2166.
［25］ Shi M， Lu LG， Fang WQ， et al. Roles played by chemolipio-dolization and embolization in chemoembolization for hepatocel-lular carcinoma： single- blind， randomized trial［J］. J Natl Cancer Inst， 2013， 105： 59- 68.
［26］ Miyayama S， Yamashiro M， Ikeda R， et al. Efficacy of superselective conventional transarterial chemoembolization using guidance software for hepatocellular carcinoma within three lesions smaller than 3 cm［J］. Cancers（Basel）， 2021， 13： 6370.
［27］ Miyayama S， Yamashiro M， Ikuno M， et al. Ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinoma guided by automated tumor- feeders detection software： technical success and short- term tumor response［J］. Abdom Imaging， 2014， 39： 645- 656.
［28］ Miyayama S， Mitsui T， Zen Y， et al. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma［J］. Hepatol Res， 2009， 39： 374- 381.
［29］ Kudo M. Proposal of primary endpoints for TACE combination trials with systemic therapy： lessons learned from 5 negative trials and the positive TACTICS trial［J］. Liver Cancer， 2018， 7： 225- 234.
［30］ Masatoshi K， Ueshima K， Kubo S， et al. Response evaluation criteria in cancer of the liver（RECICL 2015 revised version）［J］. Kanzo， 2015， 56： 116- 121.
［31］ Ding X， Sun W， Li W， et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first- line treatment for hepatocellular carcinoma with portal vein tumor thrombus： a prospective randomized study［J］. Cancer， 2021， 127： 3782- 3793.
［32］ Zhang S， Wang WS， Zhong BY， et al. Subsequent treatment after transarterial chemoembolization failure/refractoriness： a review based on published evidence［J］. J Clin Transl Hepatol， 2022， 10： 740- 747.
［33］ Huang M， Lin Q， Wang H， et al. Survival benefit of chemoem-bolization plus Iodine125 seed implantation in unresectable hepatitis B- related hepatocellular carcinoma with PVTT： a retrospective matched cohort study［J］. Eur Radiol， 2016， 26： 3428- 3436.
［34］ Zhang ZH， Zhang W， Gu JY， et al. Treatment of hepatocellular carcinoma with tumor thrombus with the use of iodine- 125 seed strand implantation and transarterial chemoembolization： a propensity- score analysis［J］. J Vasc Interv Radiol， 2018， 29：1085- 1093.
［35］ Lu J， Guo JH， Zhu HD， et al. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma： a single- center experience［J］. J Vasc Interv Radiol， 2017， 28： 786- 794.e3.
［36］ Wang W， Wang C， Shen J， et al. Integrated I- 125 Seed implantation combined with transarterial chemoembolization for treatment of hepatocellular carcinoma with main portal vein tumor thrombus［J］. Cardiovasc Intervent Radiol， 2021， 44： 1570- 1578.
［37］ Luo JJ， Zhang ZH， Liu QX， et al. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus［J］. Hepatol Int， 2016， 10： 185- 195.
［38］ Wang W， Shen J， Wang C， et al. Safety and feasibility of helical I- 125 seed implants combined with transcatheter arterial chemoembolization in hepatocellular carcinomas with main portal vein tumor thrombus［J］. Cardiovasc Intervent Radiol， 2019， 42： 1420- 1428.
［39］ Kang SH， Do YK， Soung MJ， et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA- Ⅱ levels［J］. Eur J Gastroenterol Hepatol， 2012， 24： 849- 856.
［40］ Park H， Park JY. Clinical significance of AFP and PIVKA- Ⅱ responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma［J］. Biomed Res Int， 2013， 2013：310427.
［41］ Wang E， Liu L， Xia D， et al. Chemoembolization for hepatocellular carcinoma in patients with extrahepatic spread： prognostic determinants and appropriate candidates［J］. J Vasc Interv Radiol， 2017， 28：956- 962.
［42］ Wattanasatesiri T， Kim HC， Choi JW， et al. Cone- beam CT- guided chemoembolization in patients with complete response after previous chemoembolization but subsequent elevated α- fetoprotein without overt hepatocellular carcinoma［J］. J Vasc Interv Radiol， 2019， 30： 1273- 1280.
［43］ 中国医师协会介入医师分会临床诊疗指南专委会． 中国肝细胞癌经动脉化疗栓塞（TACE）治疗临床实践指南（2021年版）［J］． 中华医学杂志， 2021， 101：1848- 1862．
［44］ 张 雯，周永杰，颜志平． 再论精细TACE［J］． 介入放射学杂志， 2021， 30：971- 975．
［45］ Mazzaferro V， Llovet JM， Miceli R， et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria： a retrospective， exploratory analysis［J］. Lancet Oncol， 2009， 10： 35- 43.
［46］ Wang Q， Xia D， Bai W， et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma：a multicentre observational study［J］. J Hepatol， 2019， 70： 893- 903.

相似文献/References:

[1]申淑群,杨业发,葛乃建,等.肝癌破裂出血的介入与外科手术疗效评价[J].介入放射学杂志,2010,(07):544.
　SHEN Shuqun,YANG Yefa,GE Naijian,et al.Evaluation of interventional and surgical treatments for the hemorrhage of ruptured hepatocellular carcinoma[J].journal interventional radiology,2010,(11):544.
[2]郑加生,崔雄伟,禹纪红.自发性肝癌破裂出血的急诊动脉栓塞治疗[J].介入放射学杂志,2006,(04):228.
　ZHANG Jia-sheng,CUI Xiong-wei,YU Ji-hong,et al.Emergency transcatheter arterial embolization for beeding of hepatocellular carcinoma spontaneous rupture[J].journal interventional radiology,2006,(11):228.
[3]李强,曾从俊,王莺.化疗栓塞联合质子放射治疗肝癌合并门脉主干癌栓的临床应用[J].介入放射学杂志,2009,(04):278.
　LI Qiang,ZENG Congjun,WANG Ying.Interventional chemoembolization combined with proton radiotherapy for the treatment of hepatocellular carcinoma accompanied with portal cancerous thrombus[J].journal interventional radiology,2009,(11):278.
[4]张长青,吴伟岗,曾志雄,等.肝动脉化疗栓塞及注射~(32)P-胶体、无水乙醇综合序贯介入治疗原发性肝癌疗效分析[J].介入放射学杂志,2000,(01):22.
[5]经 翔,丁建民,王彦冬,等. 射频消融和微波消融治疗肝癌的比较[J].介入放射学杂志,2014,(04):306.
　JING Xiang,DING Jian? min,WANG Yan? dong,et al. Ultrasound-guided percutaneous radiofrequency ablation and microwave ablation for the treatment of hepatocellular carcinoma： a comparison study[J].journal interventional radiology,2014,(11):306.
[6]钱 晟,刘 嵘,王建华,等.栓塞肝动脉-门静脉瘘在TACE联合门静脉支架治疗肝癌伴门静脉癌栓中的临床意义[J].介入放射学杂志,2015,(04):306.
　QIAN Sheng,LIU Rong,WANG Jian hua,et al.Embolization of hepatic arterio portal shunt in patients with HCC complicated by portal vein tumor thrombus treated with TACE combined with portal vein stenting： its clinical significance[J].journal interventional radiology,2015,(11):306.
[7]刘秋松,梅雀林,李彦豪,等.化疗栓塞治疗肝癌合并肝动-静脉分流的生存预后因素分析[J].介入放射学杂志,2015,(12):1056.
　LIU Qiu-song,MEI Que-lin,LI Yan-hao,et al.Interventional chemoembolization for the treatment of hepatocellular carcinoma associated with hepatic arteriovenous shunt： analysis of survival prognostic factors[J].journal interventional radiology,2015,(11):1056.
[8]刘秋松,梅雀林,何晓峰,等.索拉非尼联合PVA微粒化疗栓塞治疗肝癌并肝动-静脉分流的疗效及预后分析[J].介入放射学杂志,2016,(04):320.
　LIU Qiu- song,MEI Que- lin,HE Xiao- feng,et al.Sorafenib plus percutaneous chemoembolization with polyvinyl alcohol for hepatocellular carcinoma complicated by hepatic arteriovenous shunts： analysis of curative effect and prognosis[J].journal interventional radiology,2016,(11):320.
[9]黄 芳,龚环宇,熊正平.雷替曲塞联合奥沙利铂TACE治疗BCLC B/C期肝细胞癌的安全性及疗效[J].介入放射学杂志,2018,27(01):76.
　HUANG Fang,GONG Huanyu,XIONG Zhengping.The safety and efficacy of raltitrexed combined with oxaliplatin in TACE treatment for BCLC B/C hepatocellular carcinomas[J].journal interventional radiology,2018,27(11):76.
[10]戴高乐,罗万权,赵许亚,等.眼部Merkel细胞癌介入治疗1例[J].介入放射学杂志,2020,29(10):1060.
　DAI Gaole,LUO Wanquan,ZHAO Xuya,et al.Successful interventional treatment of Merkel cell carcinoma located at the lateral canthus of left eye： report of one case[J].journal interventional radiology,2020,29(11):1060.
[11]周卫忠,刘 圣,杨正强,等.氰基丙烯酸酯胶栓塞原发性肝细胞癌合并重度肝动脉门静脉瘘12例疗效分析[J].介入放射学杂志,2013,(08):641.
　ZHOU Wei? zhong,LIU Sheng,YANG Zheng? qiang,et al. Transarterial embolization therapy with cyanoacrylate for severe arterioportal shunt associated with hepatocellular carcinoma[J].journal interventional radiology,2013,(11):641.
[12]郑家平,邵国良,罗 君,等. 索拉非尼治疗中晚期肝细胞癌安全性和预后因素分析[J].介入放射学杂志,2014,(03):222.
　ZHENG Jia? ping,SHAO Guo? liang,LUO Jun,et al. Sorafenib for the treatment of intermediate?蛳 advanced hepatocellular carcinomas： its safety and prognostic factors[J].journal interventional radiology,2014,(11):222.
[13]万豪光,许 伟,徐 浩,等. 经导管化疗栓塞联合经皮微波消融治疗中晚期肝癌64例的预后分析[J].介入放射学杂志,2014,(06):477.
　WAN Hao- guang,XU Wei,XU Hao,et al. Transcatheter arterial chemoembolization combined with percutaneous microwave ablation for the treatment of intermediate- advanced hepatocellular carcinoma： analysis of prognostic factors in 64 cases[J].journal interventional radiology,2014,(11):477.
[14]涂文辉,罗剑钧,刘清欣,等.原发性肝癌伴门静脉主干癌栓患者存活超5年1例并文献复习[J].介入放射学杂志,2015,(12):1101.
　TU Wen- hui,LUO Jian- jun,LIU Qing- xin,et al.Primary hepatocellular carcinoma associated with portal vein tumor thrombus： report of one case with survival over 5 years and review of literature [J].journal interventional radiology,2015,(11):1101.
[15]孙 玉,张洪海,生守鹏,等.白蛋白-胆红素分级在早期肝细胞癌射频消融中的预后意义 [J].介入放射学杂志,2021,30(05):502.
　SUN Yu,ZHANG Honghai,SHENG Shoupeng,et al.Prognostic significance of albumin-bilirubin grading in patients with early hepatocellular carcinoma after radiofrequency ablation treatment[J].journal interventional radiology,2021,30(11):502.
[16]李 卿,梁 斌.化疗栓塞联合替拉扎明治疗肝癌的研究进展[J].介入放射学杂志,2021,30(08):846.
　LI Qing,LIANG Bin..Research progress in the treatment of hepatocellular carcinoma with chemoembolization combined with tirapazamine[J].journal interventional radiology,2021,30(11):846.

备注/Memo

备注/Memo:
（收稿日期：2022- 08- 29）
（本文编辑：边 佶）
更新日期/Last Update: 2022-12-09